Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts TearsBenzinga • Wednesday
Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's DataInvestors Business Daily • Wednesday
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPRNewsWire • Monday
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending StockZacks Investment Research • Monday
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDYPRNewsWire • 11/05/26
Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity DataBenzinga • 11/04/26
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised GuidanceZacks Investment Research • 11/04/26
Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say.Investors Business Daily • 11/03/26
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 10/29/26
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 10/29/26